Jefferies maintains Hana Biosciences at buy

Hana Biosciences Inc. was reiterated at a buy with a $13.00 price target by Jefferies & Co., Inc. analyst Adam Walsh following the company outlining a clear regulatory strategy for Marqibo, which is a clear positive. Consultants believe Talvesta has accelerated approval potential. The company reported third-quarter non-GAAP loss per share of $0.25, which was $0.07 below the agency's $0.18 estimate. Shares of the South San Francisco, Calif.-based development-stage biopharmaceutical company were down 7 cents, or 0.87%, at $7.97. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.